Firstly, we acknowledge that the trial was powered for the primary and key secondary outcomes that both failed to reach statistical significance and, as such, other outcomes should be interpreted with caution and not as definitive evidence of clinical benefit.
← all excerpts
Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial.
1
—
—